Lazard Asset Management
TLX

Lazard Asset Management’s Telix Pharmaceuticals TLX Stock Holding History

Lazard Asset Management’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.77M Buy
289,917
+39,400
+16% +$300K ﹤0.01% 761
2025
Q4 		$1.88M Buy
250,517
+135,893
+119% +$1.31M ﹤0.01% 894
2025
Q3 		$1.1M Buy
+114,624
New +$1.4M ﹤0.01% 1110

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Lazard Asset Management's TLX Position: Q1 2026 in Review

Lazard Asset Management increased its Telix Pharmaceuticals (TLX) stake by 16% in Q1 2026, buying an estimated $300K and bringing the position to 289,917 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #761.

Lazard Asset Management first reported a position in TLX in Q3 2025 and has held it in 3 quarters since. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Lazard Asset Management held 289,917 shares of Telix Pharmaceuticals worth $2.77M as of Q1 2026.
  • Lazard Asset Management bought 39,400 Telix Pharmaceuticals shares in Q1 2026, an estimated $300K.
  • Telix Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #761 holding.
  • Lazard Asset Management first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.